Drug firm Aurobindo Pharma on Thursday said it has received final nod from the US health regulator for its Guaifenesin extended-release tablets used as expectorant. The company has received final approval from the United States Food and Drug Administration (USFDA) to manufacture its generic Guaifenesin extended-release tablets in the strengths of 600 mg and 1,200 mg, Aurobindo Pharma said in a filing to the BSE. The product is expected to be launched in the fourth quarter of 2019-20, it added. The company's tablets are the generic version of RB Health (US) LLC's Mucinex tablets, Aurobindo Pharma said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!